TELO earnings analysis
What we found in TELO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
This 10-Q extract does not provide the income statement, balance sheet, cash flow statement, segment data, or quantitative financial outlook, so revenue, margins, EPS, cash flow, and balance-sheet trends cannot be assessed from the supplied filing text. Management reported effective disclosure controls as of June 30, 2026 and no material internal-control changes during the second quarter of 2026. The principal newly disclosed negative is a legal claim seeking more than $3.5 million; management states that there were no material changes to the risk factors in the 2025 Annual Report.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls deemed effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
- No material control changes
- The company reported no changes during the second quarter of 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
- Risk factors unchanged
- The company states that risk factors in its 2025 Annual Report remain relevant and that there have been no material changes as of the filing date.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Legal claim exceeds $3.5 million
- The Estate of Christopher Columbus Chapman, Jr. filed a complaint on June 5, 2026, claiming damages in excess of $3.5 million related to delayed transfer of restricted common stock. The company considers the claim without merit but intends to defend it vigorously.
- Controls cannot ensure full prevention
- The company cautions that its control systems provide only reasonable, not absolute, assurance and may not prevent all fraud or material error. This limitation applies despite management’s conclusion that controls were effective as of June 30, 2026.
What they said about what is next.
The filing provides no quantitative revenue or EPS guidance and does not state a change to prior outlook; financial outlook may be addressed in the August 25, 2026 earnings release or call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- Telomir Pharmaceuticals reported a net loss of approximately $990,947 for Q1 2026, a significant decrease from a loss of $2.2 million in the same quarter of 2025. The company has begun a pivotal clinical trial for its…
- 10-K · March 17, 2026
- Telomir is a preclinical-stage biotech focused on Telomir-1, an oral small molecule that modulates intracellular metal balance. The company reports multiple favorable preclinical findings and GLP toxicology described as…
- 10-Q · November 10, 2025
- Telomir reported no revenue for the quarter and a materially smaller net loss in Q3 2025 of $(1,102,294) versus $(5,990,733) in Q3 2024, producing improved EPS of $(0.03) vs $(0.20). Cash rose to $7,329,298 as of…
- 10-Q · May 14, 2025
- Telomir reported no revenue and a net loss of $2,179,828 in Q1 2025 (EPS $(0.07)), an improvement versus a net loss of $6,254,607 (EPS $(0.23)) in Q1 2024. Cash declined to $402,999 at March 31, 2025 from $1,266,131 at…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TELO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever